within Pharmacolibrary.Drugs.ATC.G;

model G03GA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0001933333333333333,
    adminDuration  = 600,
    adminMass      = 5.0,
    adminCount     = 1,
    Vd             = 0.00014000000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Serum gonadotrophin (human chorionic gonadotropin, hCG) is a hormone produced by the placenta and used primarily for fertility treatments, including induction of ovulation and support of corpus luteum function in women, and for stimulating spermatogenesis in men. It is also used in boys with cryptorchidism. The drug is administered either intramuscularly or subcutaneously. It is an established medication still used today in both female and male infertility treatments.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were estimated for a typical adult based on available pharmacological knowledge for therapeutic intramuscular administration. No direct published PK model was identified.</p><h4>References</h4><ol><li><p>Penzias, AS (2002). Luteal phase support. <i>Fertility and sterility</i> 77(2) 318–323. DOI:<a href=&quot;https://doi.org/10.1016/s0015-0282(01)02961-2&quot;>10.1016/s0015-0282(01)02961-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11821090/&quot;>https://pubmed.ncbi.nlm.nih.gov/11821090</a></p></li><li><p>Saal, W, et al., &amp; Happ, J (1991). Pharmacodynamics and pharmacokinetics after subcutaneous and intramuscular injection of human chorionic gonadotropin. <i>Fertility and sterility</i> 56(2) 225–229. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1712735/&quot;>https://pubmed.ncbi.nlm.nih.gov/1712735</a></p></li><li><p>De Geyter, C, et al., &amp; Schneider, HP (1994). Pulsatile subcutaneous versus bolus intramuscular gonadotrophin administration after pituitary suppression with a long-acting gonadotrophin-releasing hormone analogue: a controlled prospective study. <i>Human reproduction (Oxford, England)</i> 9(6) 1070–1076. DOI:<a href=&quot;https://doi.org/10.1093/oxfordjournals.humrep.a138635&quot;>10.1093/oxfordjournals.humrep.a138635</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7962378/&quot;>https://pubmed.ncbi.nlm.nih.gov/7962378</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G03GA03;
